ACN vs SYRE · P/E 24, rev $17.60B vs $7.60B cap
Accenture plc (ACN) versus Spyre Therapeutics Inc. (SYRE) — a side-by-side from cached financials, not a winner call.
Accenture plc (ACN) is a information technology services company listed on US.
Spyre Therapeutics Inc. (SYRE) is a biotechnology company listed on NASDAQ.
Latest reported ACN revenue for 2025-08-31 was $17.60B. Net income was $1.41B. Revenue was down 0.7% from 2025-05-31 to 2025-08-31. ACN currently screens at market cap $186.16B and trailing P/E 23.8.
Latest reported SYRE revenue for 2025-12-31 was $0. Net income was -$155.2M. SYRE currently screens at market cap $7.60B.
ACN currently screens at market cap $186.16B and trailing P/E 23.8. SYRE currently screens at market cap $7.60B.
Not investment advice. Open the ACN and SYRE stock pages for the full models.
Not investment advice.